THIOTEPA-BUSULFAN-FLUDARABINE CONDITIONING REGIMEN WITH ATG/PTCY-BASED GVHD PROPHYLAXIS AS PROMISING APPROACH FOR HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: A SINGLE-CENTER, OPEN-LABEL, PROSPECTIVE STUDY (EBMT 2026) - Mar 14, 2026 - Abstract #B170; Pres time: Mar 24, 2026; 06:00 PM - 07:00 PM; Location: VELAZQUEZ; "GVHD prophylaxis included ATG (6 mg/kg) plus low-dose PTCy (50 mg/kg), combined with cyclosporine, mycophenolate mofetil, and a short course of methotrexate...Letermovir was used for CMV prophylaxis; CMV reactivation occurred in 7 patients and EBV reactivation in 16, all resolving with ganciclovir, foscarnet, or rituximab... These data suggest that the TBF+ATG/PTCy regimen is feasible for haplo-HSCT in ALL, with manageable transplant-related toxicity. We will further evaluate the regimen by expanding the patient cohort and extending follow-up, which are essential for efficacy and safety analysis."
Clinical • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Lymphoma • Mucositis • T Acute Lymphoblastic Leukemia • Transplantation
|
|
Xianbo Huang1; Yanling Ren1; Shasha Wang1; Yu Xu1; Chen Mei1; Jie Jin1; Hongyan Tong1; Jiejing Qian1
|